BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30051493)

  • 1. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
    Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling.
    Li Q; Ye L; Zhang X; Wang M; Lin C; Huang S; Guo W; Lai Y; Du H; Li J; Song L; Peng X
    Cancer Lett; 2017 Aug; 402():166-176. PubMed ID: 28602974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
    Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
    Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
    Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
    Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
    Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
    J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer.
    Murillo-Garzón V; Gorroño-Etxebarria I; Åkerfelt M; Puustinen MC; Sistonen L; Nees M; Carton J; Waxman J; Kypta RM
    Nat Commun; 2018 May; 9(1):1747. PubMed ID: 29717114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
    Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
    Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
    Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
    Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic ETS Factors in Prostate Cancer.
    Nicholas TR; Strittmatter BG; Hollenhorst PC
    Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expression of Proto-Oncogene
    Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETS transcription factor ERG cooperates with histone demethylase KDM4A.
    Kim TD; Shin S; Janknecht R
    Oncol Rep; 2016 Jun; 35(6):3679-88. PubMed ID: 27109047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
    Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
    Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
    Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
    Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.